Adrian U. Wiestner

Hematology
10 Center Dr
Bethesda, MD 20892

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 150 publications

Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib.

Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib.

Journal: Heart rhythm
Published: July 02, 2025

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.

Journal: Blood
Published: June 06, 2025

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.

Journal: Blood
Published: June 06, 2025

Numbat-multiome: inferring copy number variations by combining RNA and chromatin accessibility information from single-cell data.

Numbat-multiome: inferring copy number variations by combining RNA and chromatin accessibility information from single-cell data.

Journal: Briefings in bioinformatics
Published: June 04, 2025

Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.

Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: March 20, 2025

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.

Journal: Leukemia & lymphoma
Published: February 20, 2025

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.

Journal: Leukemia
Published: February 04, 2025

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells.

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells.

Journal: Blood
Published: May 17, 2024

Genomic risk stratification in chronic lymphocytic leukemia.

Genomic risk stratification in chronic lymphocytic leukemia.

Journal: Clinical advances in hematology & oncology : H&O
Published: January 31, 2024

Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.

Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.

Journal: Leukemia & lymphoma
Published: September 21, 2023

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.

Journal: Blood
Published: July 31, 2023

Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.

Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.

Journal: Haematologica
Published: March 23, 2023
Showing 1-12 of 150

Last Updated: 09/26/2026